Amylyx Pharmaceuticals, Inc. (AMLX)

Market Cap	1.55B +479.8%
Revenue (ttm)	n/a
Net Income	-144.74M
EPS	-1.53
Shares Out	110.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	333,502
Open	13.98
Previous Close	13.79
Day's Range	13.65 - 14.17
52-Week Range	3.11 - 17.49
Beta	-0.30
Analysts	Strong Buy
Price Target	20.11 (+43.75%)
Earnings Date	Mar 3, 2026

About AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: AMLX
• Website: https://amylyx.com

Analyst Summary

According to 9 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $20.11, which is an increase of 43.75% from the latest price.

Price Target

$20.11

(43.75% upside)

Analyst Consensus: Strong Buy